EUVIMEDObjevte EUVIMED
Crossref

Animal‐to‐Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects

Martin Beliveau, Igor Rubets, Drobic Bojan, Christine Hall, Derek Toth, Shantha Kodihalli, Srinivas Kammanadiminti iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3097 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, 2024. Written by Martin Beliveau and 6 co-authors. Institution: Integrated Drug Development, Certara, Montreal, Quebec, Canada. Major MEDLINE topics: Anthrax, Antitoxins, Anthrax Vaccines, Respiratory Tract Infections. 51 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Anthrax Immune Globulin Intravenous (AIGIV [ANTHRASIL]), was developed for the treatment of toxemia associated with inhalational anthrax. It is a plasma product collected from individuals vaccinated with anthrax vaccine and contains antitoxin IgG antibodies against Bacillus anthracis protective antigen. A pharmacokinetic (PK) and exposure–response model was constructed to assess the PKs of AIGIV in anthrax‐free and anthrax‐exposed rabbits, non‐human primates and anthrax‐free humans, as well as the relationship between AIGIV exposure and survival from anthrax, based on available preclinical/clinical studies. The potential effect of anthrax on the PKs of AIGIV was evaluated and estimates of survival odds following administration of AIGIV protective doses with and without antibiotic co‐treatment were established. As the developed PK model can simulate exposure of AIGIV in any species for any dosing scenario, the relationship between the predicted area under the concentration curve of AIGIV in humans and the probability of survival observed in preclinical studies was explored. Based on the simulation results, the intravenous administration of 420 U (units of potency as measured by validated Toxin Neutralization Assay) of AIGIV is expected to result in a > 80% probability of survival in more than 90% of the human population. Additional simulations suggest that exposure levels were similar in healthy and obese humans, and exposure in pediatrics is expected to be up to approximately seven‐fold higher than in healthy adults, allowing for doses in pediatric populations that ranged from one to seven vials. Overall, the optimal human dose was justified based on the PK/pharmacodynamic (PD) properties of AIGIV in animals and model‐based translation of PK/PD to predict human exposure and efficacy.

Subjects

MeSH terms (MEDLINE)

AnthraxAntitoxinsAnthrax VaccinesRespiratory Tract InfectionsAdultAnimalsHumansRabbitsChildImmunoglobulin GAnti-Bacterial AgentsAntigens, Bacterial

Substances

Anthrax Immune Globulin IntravenousImmunoglobulin GAntitoxinsAnthrax VaccinesAnti-Bacterial AgentsAntigens, Bacterial

Authors and institutions

  • Integrated Drug Development, Certara, Montreal, Quebec, Canada.
  • Emergent BioSolutions Inc., Winnipeg, Manitoba, Canada.

ORCID profiles: Srinivas Kammanadiminti

Cite

APA

Beliveau, M., Rubets, I., Bojan, D., Hall, C., Toth, D., Kodihalli, S., & Kammanadiminti, S. (2024). Animal‐to‐Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3097

Vancouver

Beliveau M, Rubets I, Bojan D, Hall C, Toth D, Kodihalli S, et al. Animal‐to‐Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3097

BibTeX
@article{Beliveau2024,
  author = {Beliveau, Martin and Rubets, Igor and Bojan, Drobic and Hall, Christine and Toth, Derek and Kodihalli, Shantha and Kammanadiminti, Srinivas},
  title = {Animal‐to‐Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3097}
}
Start for free →